Another EU vaccine failure as Germany's CureVac jab is found to only have 47% efficacy - wiping billions from the company's share price
The results from a trial with 40,000 participants have caused CureVac shares in Frankfurt and New York to fall more than 50 per cent, erasing more than 5billion from the company…
